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 Abstract 
  Background:   Vascular risk factors (VRF) may influence response to rivastigmine in Alzheimer’s 
disease (AD).  Methods:  AD patients who participated in a randomized, double-blind, placebo-
controlled trial of rivastigmine patch and capsule treatment were stratified by baseline VRF 
  status. Treatment response was evaluated using the AD Assessment Scale-cognitive subscale 
(ADAS-cog), AD Cooperative Study-Clinical Global Impression of Change (ADCS-CGIC) and   the 
AD Cooperative Study-Activities of Daily Living (ADCS-ADL) scale.   Results:   ADAS-cog scores 
significantly improved in all rivastigmine-treated patients (p   !   0.05 vs. placebo), except 9.5 
mg/24 h patch-treated patients with VRF, and were significantly affected by VRF status in the 
study population as a whole.   Significant benefits were seen on the ADCS-ADL in 9.5 mg/24 h 
patch- and capsule-treated   patients with, but not without, VRF. The ADCS-CGIC significantly 
improved in capsule-treated patients with, and patch-treated patients without VRF. Although 
n o n - s i g n i fi c a n t ,  p a t i e n t s    w i t h o u t  V R F  s h o w e d  a n  a p p a r e n t  f a s t e r  r a t e  o f  p l a c e b o  d e c l i n e .  
  Conclusion:   VRF may   influence AD progression and response to rivastigmine. 
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 Introduction 
  The cholinesterase inhibitor rivastigmine is approved in the USA and a number of
other countries worldwide for the symptomatic treatment of mild-to-moderate Alzheimer’s 
disease (AD). Rivastigmine is available as oral capsules, but it is also the first AD therapy to 
be licensed as a transdermal patch. 
    The rivastigmine transdermal patch provides steady plasma concentrations of rivastig-
mine and bypasses first-pass metabolism in the gut and liver  [1] . The efficacy of oral rivastig-
mine is thought to be dose-dependent   [2, 3]  . However, oral rivastigmine treatment may be 
associated with a number of gastrointestinal side effects, such as nausea and vomiting, which 
may limit the maximum therapeutic dose that can be achieved by some patients   [4]  .
    A large, international, 24-week, multicenter, randomized, double-blind, placebo- and 
active-controlled trial (Investigation of transDermal Exelon in ALzheimer’s disease; IDEAL) 
compared the efficacy, safety, and tolerability of rivastigmine patch (9.5 mg/24 h [10 cm  2 ] 
and 17.4 mg/24 h [20 cm  2 ]), rivastigmine capsules (12 mg/day), and placebo  [5] .   The rivastig-
mine 9.5 mg/24 h patch was associated with comparable efficacy to 12 mg/day capsules, but 
superior tolerability, as there were approximately two-thirds fewer reports of gastrointestinal 
adverse events in the patch group than the capsule group  [5] . This improved tolerability may 
allow access to higher doses, leading to enhanced treatment benefits   [6, 7]  .
  The concept of ‘responders’ and ‘non-responders’ to cholinesterase inhibitor therapy has 
been discussed for a number of years, and has a variable impact on the efficacy of treatment 
reported in clinical trials   [8]  . Suboptimal dosing may be associated with a lower probability 
of showing a response to cholinesterase inhibitor therapy, reflecting the dose-response 
 relationship seen with these agents  [2, 3] . As well as dose, it has been suggested that a number 
of other variables, including age   [9]  , disease stage   [10, 11]  , and the presence of vascular risk 
factors (VRF)   [12, 13]  , may influence the response to cholinesterase inhibitors such as riv-
astigmine. To date, associations between the presence of VRF and prediction of response to 
rivastigmine have been based on trials with oral capsules  [12, 13] . The IDEAL study provides 
us with a large database whereby similar analyses may be performed to investigate whether 
the presence of concurrent VRF may predict response to transdermal as well as oral rivastig-
mine.
  M e t h o d s  
 This was a retrospective analysis of a large, international, 24-week, randomized, double-
blind, placebo- and active-controlled trial (CENA713D2320, IDEAL) which investigated the 
efficacy, safety, and tolerability of rivastigmine capsule (12 mg/day), rivastigmine patch (9.5 
and 17.4 mg/24 h), and placebo   [5]  .
    The full details of the IDEAL study have been published previously   [5]  . Briefly, patients 
were 50–85 years of age, with a diagnosis of probable AD (DSM-IV, NINCDS/ADRDA 
  criteria)   [14, 15]   and a Mini-Mental State Examination (MMSE) score of 10–20   [16]  . Patients 
were excluded from study entry if they had: any form of advanced, progressive or unstable 
disease that may have affected safety, or the ability to complete assessments; a diagnosis of 
any condition other than AD that may cause dementia (e.g., vascular dementia); used any 
new psychotropic or dopaminergic agents, cholinesterase inhibitors, or centrally acting 
  cholinergic agents during the 4 weeks prior to randomization; a history (past year) or exist-
ing diagnosis of cerebrovascular disease, e.g., stroke, transient ischemic attack, and/or aneu-
rysms, and an existing diagnosis of severe cardiovascular disease.152
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    A brain scan (magnetic resonance imaging) was performed at screening, if a scan had 
not been performed in the previous 12 months, to ensure patients met the entry criteria and 
exclude patients with probable vascular dementia. Patients with a score   1   4 on the Modified 
Hachinski Ischemia Scale (suggestive of vascular dementia) were excluded. Laboratory tests 
(total cholesterol and homocysteine) were performed at screening, providing information on 
VRF in the study participants. 
    S t u d y  p a r t i c i p a n t s  w e r e  r a n d o m i z e d  t o  r e c e i v e  1 2  m g / d a y  r i v a s t i g m i n e  c a p s u l e s ,  
9.5 mg/24 h rivastigmine patch, 17.4 mg/24 h rivastigmine patch, or placebo. Patients were 
up-titrated to their target dose in 4-week steps over a 16-week period and then maintained 
at their target dose for a further 8 weeks. Protocols and study materials were reviewed by the 
responsible overseeing institutional review board for each site/country. All subjects provided 
informed consent before participating in the study. The study was conducted according to 
the ethical principles of the Declaration of Helsinki, as revised in 2000.
    Primary outcome measures included the change from baseline at week 24 on the AD 
Assessment Scale-cognitive subscale (ADAS-cog)   [17]   and the week-24 AD Cooperative 
Study-Clinical Global Impression of Change (ADCS-CGIC) score   [18]  . Secondary outcome 
measures included the change from baseline at week 24 on the ADCS-Activities of Daily 
  Living (ADCS-ADL) scale   [19]  . Safety evaluations included monitoring vital signs and skin 
tolerability, and reporting of all adverse events. Efficacy analyses were based on the intent-
to-treat (ITT) principle, with all patients who had received at least 1 dose of study medication 
and provided at least 1 baseline and 1 post-baseline efficacy assessment included in the anal-
yses [ITT last observation carried forward (LOCF) population]. 
    In the current analysis, patients in the ITT-LOCF population were stratified, relative to 
their allocated treatment group, according to whether their case report forms documented 
  6   1 active VRF at screening. VRF were active at study entry. VRF reported in the study 
  population at screening included: angina pectoris; arteriosclerosis; atherosclerosis; atrial 
  fibrillation; raised blood homocysteine; carotid artery disease; carotid artery stenosis; 
  cerebral artery embolism; cerebral atherosclerosis; cerebral ischemia; decreased cerebral 
  perfusion pressure; coronary angioplasty; coronary artery atherosclerosis; coronary artery 
disease; diabetes mellitus; insulin-dependent diabetes mellitus; non-insulin-dependent 
  diabetes mellitus; diabetic microangiopathy; essential hypertension; hypercholesterolemia; 
hyperglycemia; hyperlipidemia; hypertension; hypertensive heart disease; hypertriglyceri-
demia; myocardial infarction; myocardial ischemia; obesity; peripheral ischemia; peripheral 
occlusive disease; peripheral vascular disorder; quadruple-vessel bypass graft, and vascular 
and venous insufficiency.
    The mean change [least-square (LS) means] from baseline at week 24 on the ADAS-cog 
(total, domains and individual items) and ADCS-ADL, and week-24 ADCS-CGIC scores (LS 
means) were assessed relative to treatment and VRF status for the ITT-LOCF population. 
Effect sizes were calculated using Cohen’s d for each of the individual ADAS-cog items. The 
statistical significance of treatment differences on the ADAS-cog and ADCS-ADL was 
  assessed using an analysis of covariance (ANCOVA) model, with treatment, VRF, treatment 
by VRF, and country as factors, and baseline scores as a covariate. Treatment differences on 
the ADCS-CGIC were assessed using an ANCOVA model, with treatment, VRF, treatment 
by VRF and country as factors. Additional evaluations included the effect of VRF on the 
  incidence of adverse events and the rate of placebo decline. Analysis of placebo decline was 
based on the ITT observed case (ITT-OC) population and compared using an analysis of 
variance (ANOVA) model.153
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  R e s u l t s  
 Patients 
  In total, 1195 patients were entered in the IDEAL study: 293 were randomized to receive 
the rivastigmine 9.5 mg/24 h patch; 303 to the rivastigmine 17.4 mg/24 h patch; 297 to the 
rivastigmine 12 mg/day capsule and 302 to placebo. Of these patients, 636 were defined as 
having concurrent VRF at baseline, based on their medical history and ‘active’ comorbid 
conditions reported during the screening visit. 
    The baseline characteristics of the study population are summarized in   table 1  . Patients 
in the rivastigmine-treated and placebo groups were comparable at baseline in terms of their 
gender, race and scores on the MMSE, ADAS-cog and ADCS-ADL scales. However, on 
  average, patients with concurrent VRF tended to be slightly older and have a higher body 
weight than patients without concurrent VRF at baseline (  table 1  ). 
    The loading dose of the 9.5 mg/24 h patch is 18 mg and the 17.4 mg/24 h patch has 
a loading dose of 36 mg   [20]  . The last prescribed rivastigmine dose was calculated, in terms 
of loading dose, for patients with and without concurrent VRF (safety population). The mean 
(standard deviation; SD) last prescribed doses for patients with concurrent VRF in the 
9.5 mg/24 h patch, 17.4 mg/24 h patch, and 12 mg/day capsule groups were 17.0 (2.8), 
28.8 (10.2), and 9.3 (3.6) mg, respectively. For patients without concurrent VRF at baseline, 
the mean (SD) last prescribed doses for the 9.5 mg/24 h patch, 17.4 mg/24 h patch and the 
12 mg/day capsule groups were 17.3 (2.4), 27.7 (9.4), and 9.2 (3.5) mg, respectively.
    Rate of Placebo Decline 
  There was an apparent faster decline in the placebo group from baseline at week 24 on 
the ADAS-cog in patients who did not show signs of concurrent VRF at baseline compared 
with patients with concurrent VRF (  fig. 1  ). However, the observed differences did not reach 
significance (p = 0.154). 
  E f f i c a c y  
  Rivastigmine-treated patients showed significant improvements from baseline at week 
24 on the ADAS-cog (  table 2  ). When stratifying patients by their VRF status, significant 
i m p r o v e m e n t s  w e r e  s e e n  f r o m  b a s e l i n e  a t  w e e k  2 4  o n  t h e  A D A S - c o g  i n  r i v a s t i g m i n e  
17.4 mg/24 h patch- and capsule-treated patients with concurrent VRF, and in all rivastig-
mine-treated groups for patients without concurrent VRF (all p   !   0.05 vs. placebo;   table 2  ; 
  fig. 1  ). ADAS-cog performance did not differ significantly between patients with and with-
out VRF in the individual treatment groups (all p   1   0.05 vs.    placebo;   table 2 ).  However, 
significant differences in ADAS-cog performance were seen between patients with and 
without concurrent VRF when comparing the study population as a whole (p = 0.041).
    Across the whole study population, the mean change from baseline at week 24 on the 
ADAS-cog language domain was significantly different between patients with and without 
concurrent VRF (p = 0.005). When considering the individual treatment groups, significant 
differences on the ADAS-cog language domain were observed between patients with and 
without concurrent VRF randomized to receive placebo (p = 0.010), with patients without 
concurrent VRF showing an apparent faster rate of placebo decline. Of the individual items 
that comprise the language domain, significant differences were observed between patients 
with and without concurrent VRF on items that assess commands, spoken language ability 
and word finding difficulty (p = 0.024, p = 0.0008, and p = 0.030, respectively). These differ-
ences also reached significance on the spoken language ability item for capsule-treated 
  patients (p = 0.033 VRF vs. no VRF) and the spoken language ability, word finding difficul-
ty, and comprehension items for patients who received placebo (p = 0.044, p = 0.028, p = 0.020 155
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VRF vs. no VRF, respectively). VRF status was not shown to have any significant effect on 
the ADAS-cog memory (p = 0.211 VRF vs. no VRF) or praxis (p = 0.362 VRF vs. no    VRF) 
domains, or the items which comprise these domains (with the exception of word recall 
amongst patients who received placebo, p = 0.035 VRF vs. no VRF).
    Effect sizes were calculated for each of the individual ADAS-cog items by treatment 
group and VRF status. When comparing the magnitude of the effect sizes between patients 
with and without concurrent VRF, there was an overall trend toward a greater effect size on 
the individual ADAS-cog items in patients without concurrent VRF (  fig. 2  ). Patch-treated 
patients without concurrent VRF had fewer items with an effect size   !   0.1, and more items 
with an effect size   1   0.2 than patch-treated patients with concurrent VRF (  fig. 2  ). 
  Rivastigmine patch- and capsule-treated patients also showed significant improvements 
at week 24 on the ADCS-CGIC (p  !  0.05 vs. placebo;  table 2 ). When taking the patients’ VRF 
  Fig. 1.   Mean change from base-
line at week 24 on the ADAS-cog 
by treatment and VRF status 
(ITT-LOCF population).   *  p    !  
0.05 vs. placebo,   *  *  p   !   0.01 vs. 
placebo (LS means).  
  Fig. 2.   Effect sizes for each of the 
individual ADAS-cog items by 
treatment and VRF status.  156
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Table 2.   Mean change from baseline at week 24 on the ADAS-cog and ADCS-ADL, and mean week-24 ADCS-CGIC score 
by treatment and VRF status (ITT-LOCF population)
R ivastigmine Placebo
9.5 mg/24 h 
patch
17.4 mg/24 h 
patch
12 mg/day 
capsule
All patients
ADAS-cog, n
Mean8SD
p value vs. placeboa
248
–0.5986.37
0.005
262
–1.6086.53 
<0.0001
253 
–0.6286.22
0.003
281
0.9786.80
–
ADCS-CGIC, n
Mean8SD
p value vs. placeboa
248
3.9181.20
0.012
260
3.9681.27
0.022
253
3.9181.25
0.010
278
4.1981.26
–
ADCS-ADL, n 
Mean8SD 
p value vs. placeboa
247
–0.1489.07
0.017
263 
–0.02811.60
0.016
254 
–0.4889.50
0.040
281 
–2.2789.36
–
Patients with concurrent VRF (VRF)
ADAS-cog, n
Mean8SD 
p value vs. placeboa
p value VRF vs. no VRFa
141
–0.6686.44
0.130
0.663
138
–1.7286.58
0.004
0.644
129
–1.3285.90
0.023
0.083
155
0.4586.82
–
0.096
ADCS-CGIC, n
Mean8SD 
p value vs. placeboa
p value VRF vs. no VRFa
140
3.9081.17
0.147
0.672
136
3.9981.26
0.411
0.735
128 
3.7881.24
0.029
0.071
153
4.1281.35
–
0.195
ADCS-ADL, n 
Mean8SD
p value vs. placeboa
p value VRF vs. no VRFa
140
0.1688.69
0.027
0.313
138
–0.19812.36
0.116
0.925
130 
0.09810.11
0.041
0.200
155
–2.39810.15
–
0.783
Patients without concurrent VRF (no VRF)
ADAS-cog, n
Mean8SD
p value vs. placeboa
107
–0.4986.31
0.014
124 
–1.4886.50
0.0001
124
0.1086.47
0.046
126
1.6186.75
–
ADCS-CGIC, n
Mean8SD
p value vs. placeboa
108
3.9381.25
0.038
124
3.9281.28
0.019
125 
4.0581.26
0.135
125
4.2881.15
–
ADCS-ADL, n 
Mean8SD
p value vs. placeboa
107
–0.5389.57
0.224
125
0.17810.75
0.069
124
–1.0888.82
0.375
126
–2.1188.32
–
a p   values calculated from LS means.
status into consideration, rivastigmine capsule-treated patients with concurrent VRF and 
patch-treated (9.5 and 17.4 mg/24 h) patients without concurrent VRF showed significant 
improvements (p = 0.029, p = 0.038, p = 0.019 vs.     placebo, respectively) at week 24 on
the ADCS-CGIC (  table 2  ;   fig. 3  ). Despite rivastigmine 9.5 mg/24 h patch- and 12 mg/day 
capsule-treated patients with concurrent VRF showing a trend towards better performance 
on the ADCS-CGIC than patients without concurrent VRF, VRF status did not have a 
  significant effect on week 24 ADCS-CGIC scores (p = 0.672, p = 0.071 VRF vs. no VRF; 
 respectively;   table 2 ;   fig. 3 ). 157
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    Significant benefits of treatment were seen on the ADCS-ADL from baseline at week 24 
i n  r i v a s t i g m i n e  p a t c h -  a n d  c a p s ul e - t r e a t e d  p a t i e n t s  c o m p a r e d  wi th  p l a c e b o  ( p    !   0.05;
 table 2 ). More specifically, rivastigmine 9.5 mg/24 h patch- and capsule-treated patients with 
concurrent VRF, but not those without, showed significant changes from baseline at week 24 
on the ADCS-ADL (p = 0.027, p = 0.041 vs. placebo, respectively;  table 2 ;  fig. 4 ). Rivastigmine 
9.5 mg/24 h patch- and capsule-treated patients with concurrent VRF showed a numerical 
trend towards better performance on the ADCS-ADL than patients without concurrent VRF 
(  fig. 4  ). However, these differences did not reach significance (p   1   0.05 VRF vs. no VRF) 
across any of the treatment groups (  table 2  ), or in the study population as a whole.
  S a f e t y  
  Overall, there was a significant difference in the incidence of adverse events between 
patients with and without concurrent VRF (61.5 and 51.2%, respectively; p = 0.0004 VRF vs. 
no VRF;  table 3 ). In each of the individual treatment groups, the overall incidence of adverse 
events was slightly higher in those patients who had concurrent VRF at baseline compared 
with those without (58.9 vs. 40.6% in the 9.5 mg/24 h patch group, 68.4 vs. 63.5% in the 17.4 
mg/24 h patch group, and 68.0 vs. 58.5% in the 12 mg/day capsule group, respectively;   table 3 ). 
  Fig. 3.   Mean ADCS-CGIC score 
at week 24 by treatment and VRF 
status (ITT-LOCF population). 
* p  !  0.05 vs. placebo (LS means).  
  Fig. 4.   Mean change from base-
lin e  a t  w eek  24  o n  th e  ADCS-
ADL by treatment and VRF 
  status (ITT-LOCF population).
  *  p  !  0.05 vs. placebo (LS means). 158
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However, the same trend was also seen in patients in the placebo group (51.8 vs. 39.7%, re-
spectively;   table 3  ). Irrespective of VRF status, the most common adverse events reported by 
rivastigmine-treated patients were cholinergic in nature, including nausea, vomiting, and 
diarrhea (  table 3  ). The incidence of nausea and vomiting tended to be lower in patients with 
and without concurrent VRF treated with the 9.5 mg/24 h patch compared with 12 mg/day 
capsules (  table 3  ). Of the adverse events reported by   1   5% of patients in any treatment group 
after stratifying by VRF status, the incidence of diarrhea and dizziness were significantly 
different when comparing patients with and without concurrent VRF (p   !   0.05 VRF vs. no 
VRF;   table 3 ). 
  Discussion 
  In this retrospective analysis of the IDEAL study, we investigated the effect of VRF on 
the response to oral and transdermal rivastigmine. Significant improvements were seen on 
the ADAS-cog (compared with placebo) in all rivastigmine-treated patients, except for 9.5 
mg/24 h patch-treated patients with concurrent VRF. Significant treatment benefits were 
observed on the ADCS-ADL in 9.5 mg/24 h patch- and capsule-treated patients with, but not 
without, concurrent VRF . ADCS-CGIC scores significantly improved in capsule-treated 
  patients with and patch-treated patients without VRF. VRF status had a significant effect on 
ADAS-cog performance when comparing the study population as a whole, but no significant 
effects on efficacy were observed when comparing the individual treatment groups.
However, VRF status was shown to have a significant effect on performance on the language 
domain of the ADAS-cog, and 3 of 4 items (commands, word finding difficulty, and spoken 
language ability) that comprise this domain. Although these findings require further inves-
tigation, they suggest that VRF may impact on language aspects of cognition, in terms of the 
rate of decline and the degree of symptomatic improvement observed over 24 weeks. 
    Overall, although non-significant, VRF status appeared to have a greater influence on 
the efficacy (total ADAS-cog, ADCS-CGIC, and ADCS-ADL scores) of oral than transder-
mal rivastigmine. These observations suggest that the higher peak plasma concentrations
of rivastigmine observed with oral compared with transdermal treatment may offer some 
benefits in patients with VRF, despite the greater potential for adverse events. 
    Other studies have reported that rivastigmine capsule treatment is associated with 
  greater efficacy in patients with concurrent VRF   [12, 13]  . A 104-week, open-label extension 
of a 26-week, placebo-controlled trial of rivastigmine capsule treatment in patients with 
mild-to-moderate AD found that hypertensive AD patients who had received rivastigmine 
capsules during both phases of the study showed greater benefits of treatment than patients 
who had switched to rivastigmine (from placebo) at the start of the open-label extension. In 
contrast, treatment duration did not appear to have any significant effect on the efficacy of 
rivastigmine treatment in non-hypertensive patients   [12]  . A study examining the efficacy, 
safety, and tolerability of rivastigmine capsules in patients with and without concurrent VRF 
found that rivastigmine was equally safe and well-tolerated in both groups of patients, but 
patients with concurrent VRF showed increased benefits of treatment on cognition and ADL 
  [13]  . A further study has demonstrated that treatment with oral rivastigmine is associated 
with efficacy in patients both with and without concurrent hypertension   [21]  . However, 
treatment with 6–12 mg/day rivastigmine capsules was associated with significantly greater 
efficacy on the ADAS-cog than 1–4 mg/day rivastigmine capsules in hypertensive but not 
non-hypertensive patients   [21]  . 
    Although non-significant, patients without concurrent VRF appeared to show a trend 
towards a faster rate of placebo decline on the ADAS-cog than patients with concurrent VRF. 160
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A similar trend (p values not reported) was observed in the ADAS-cog data from a study 
examining the effect of concurrent arterial hypertension on the efficacy of rivastigmine 
  capsules in AD patients   [21]  . In the current analysis, we observed a shift towards a greater 
effect size on individual ADAS-cog items in rivastigmine-treated patients without concur-
rent VRF. The trend towards greater placebo decline observed in patients without concurrent 
VRF on the total ADAS-cog and some items may have increased the effect size in these 
  patients, as effect sizes take into account drug–placebo differences. These findings may be 
interesting to investigate further, as they suggest that there may be differences in the brain 
physiology of patients with VRF that may influence disease progression.
    Imaging studies have shown that patients who respond to rivastigmine show increased 
frontal, temporal, and parietal regional cerebral blood flow when compared with untreated 
patients or ‘non-responders’   [22, 23]  . These increases in blood flow have been correlated
with improvements in cognition, memory, and attention. These findings may explain, in 
part, why patients with VRF, who may have high blood pressure, damaged blood vessels, and 
physiological changes in blood flow, appear to demonstrate an enhanced response to 
 rivastigmine. 
    This analysis was designed to investigate the efficacy, safety, and tolerability of oral and 
transdermal rivastigmine in patients with mild-to-moderate AD and concurrent VRF. This 
was a retrospective analysis of one grouping of VRF that was limited by multiple compari-
sons and lack of direct imaging data on brain ischemic changes, and hence was only intend-
ed to be hypothesis forming. No corrections were made for multiple comparisons due to the 
exploratory nature of the analyses. The IDEAL study was not powered to detect treatment 
differences between AD patients with and without concurrent VRF at baseline. These factors 
impact on the robustness of the data, and must be taken into consideration when interpret-
ing the results. 
    In conclusion, these data suggest that rivastigmine treatment may benefit patients both 
with and without concurrent VRF. However, VRF status may impact on aspects of the 
  observed treatment response, such as cognition, and more specifically, language. Larger 
studies are needed to confirm these findings and fully investigate the effect of concurrent 
VRF on the efficacy, safety, and tolerability of rivastigmine in mild-to-moderate AD. In par-
ticular, the effect of VRF on the rate of placebo decline and disease progression warrants 
further investigation, as this may be clinically important when considering optimal treat-
ment strategies for patients with a number of comorbid conditions. 
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